Boston Scientific Q3 2026: sales up 1.5%, EPS down, Q4 guided lower
Boston Scientific grew third-quarter 2026 sales just 1.5% to $5.138 billion, but adjusted EPS slipped to $0.73 and gross margin fell to 66.7%, and management now guides fourth-quarter sales to shrink. Read it as a margin story: volume held, cost of products sold jumped to $1.710 billion, and the August cybersecurity incident still hangs over the fourth quarter.
1 · Expected vs. Actual
Free preview belowGAAP EPS was $0.40 against $0.51 a year ago, and adjusted EPS of $0.73 landed just above the $0.7233 consensus while still trailing last year's $0.75. The $0.33 gap between adjusted and GAAP is mostly the usual accounting, with amortization alone worth $0.14 a share and litigation and restructuring charges adding $0.04 and $0.05. Reported net income fell to $582 million from $755 million.
Net sales of $5.138 billion rose 1.5% from $5.065 billion a year ago, with no help from currency because the foreign-exchange impact rounded to nil. Sequentially, sales fell from $5.442 billion in the second quarter of 2026. Cardiovascular carried the quarter at $3.406 billion (+1.9%) while MedSurg managed $1.733 billion (+0.6%) as Urology dropped 3.2%.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-03
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.